




Mark Berlin (Autor)

## Predicting Oral Absorption of Poorly Soluble Weakly Basic Drugs

Mark Berlin

### Predicting Oral Absorption of Poorly Soluble Weakly Basic Drugs



Cuvillier Verlag Göttingen  
Internationaler wissenschaftlicher Fachverlag

<https://cuvillier.de/de/shop/publications/7128>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen,  
Germany

Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>



# Index

<b>1</b>	<b>Introduction .....</b>	<b>1</b>
1.1	Drug transit through the upper GI tract.....	2
1.2	Determinants of drug absorption .....	4
1.2.1	The biopharmaceutics classification system .....	4
1.2.2	The biopharmaceutics drug disposition classification system.....	5
1.2.3	The developability classification system .....	6
1.3	Weak bases and the GI tract.....	7
1.3.1	pH in the GI tract .....	7
1.3.2	Bile salts and food in the GI tract .....	9
1.3.3	Gastric emptying .....	10
1.4	Simulation of <i>in vivo</i> drug dissolution .....	10
1.4.1	Dissolution media simulating GI fluids .....	10
1.4.2	Simulation of GI dissolution conditions .....	11
1.5	Drug permeability assessment .....	14
1.6	Physiologically based pharmacokinetic modeling .....	16
1.6.1	PBPK modeling approaches .....	16
1.6.2	Software for PBPK modeling.....	17
1.6.2.1	<i>MATLAB<sup>®</sup> and STELLA<sup>®</sup></i> .....	17
1.6.2.2	<i>Commercial software (Simcyp<sup>®</sup>, GastroPlus<sup>®</sup>, PK-Sim<sup>®</sup>) and GI-Sim<sup>®</sup></i> .....	18
1.7	Aims of this work .....	20
<b>2</b>	<b>Materials and Methods.....</b>	<b>21</b>
2.1	Materials.....	21
2.1.1	Chemicals .....	21
2.1.2	Model substance cinnarizine.....	22
2.1.3	Model substance atazanavir .....	24
2.2	Methods.....	28
2.2.1	HPLC-UV setup.....	28
2.2.2	Biorelevant media .....	29
2.2.3	Solubility assessment.....	31
2.2.4	Dissolution experiments .....	33
2.2.5	“Dumping” experiments.....	33
2.2.6	Transfer experiments .....	33
2.2.7	WinNonLin <sup>®</sup> - assessment of pharmacokinetics of API formulations .....	38
2.2.8	STELLA <sup>®</sup> .....	39
2.2.9	Simcyp <sup>®</sup> .....	47
2.2.10	Statistical comparison of predicted plasma profiles using different transfer experiment approaches .....	51



<b>3</b>	<b>Results</b> .....	<b>52</b>
3.1	Cinnarizine – investigation of <i>in vitro</i> behavior .....	52
3.1.1	Solubility results .....	52
3.1.2	Dissolution of cinnarizine tablets in biorelevant media.....	53
3.1.3	Dumping of pure cinnarizine .....	57
3.1.4	Investigation of supersaturation and precipitation of cinnarizine during transfer experiments .....	58
3.2	Cinnarizine - <i>in silico</i> plasma profile simulation.....	66
3.2.1	Evaluation of distribution and elimination kinetics of various cinnarizine tablets using WinNonLin® .....	66
3.2.2	STELLA® model - investigation of permeability restrictions of cinnarizine using fed state simulations .....	67
3.2.3	STELLA® “dissolution-only” vs. “supersaturation and precipitation” PBPK model in cinnarizine fasted state simulations.....	69
3.2.4	STELLA® statistical comparison analysis of different transfer rates .....	73
3.2.5	STELLA® sensitivity analysis of cinnarizine plasma profile predictions .....	74
3.2.6	Summary of cinnarizine plasma profile simulations using Simcyp® .....	77
3.3	Summary of the cinnarizine investigation and formulation suggestions.....	78
3.4	Atazanavir sulfate – investigation of <i>in vitro</i> behavior .....	80
3.4.1	Solubility results .....	80
3.4.1.1	<i>Equilibrium solubility</i> .....	80
3.4.1.2	<i>Kinetic solubility</i> .....	82
3.4.2	Dissolution results of atazanavir sulfate capsules in biorelevant media .....	83
3.4.3	Dumping results of atazanavir sulfate .....	87
3.4.4	Investigation of the atazanavir sulfate concentration profile during simulated transfer from the stomach to the intestine .....	88
3.5	Atazanavir sulfate - <i>in silico</i> plasma profile simulation .....	95
3.5.1	Evaluation of distribution and elimination kinetics of atazanavir using WinNonLin® analysis of literature PK data .....	95
3.5.2	Permeability evaluation of atazanavir .....	96
3.5.3	STELLA® plasma profile predictions of atazanavir capsules in the fasted state .....	97
3.5.4	STELLA® sensitivity analysis on atazanavir plasma profile predictions .....	104
3.6	Summary of atazanavir plasma profile simulations using Simcyp® .....	109
3.7	Summary of the atazanavir investigation and formulation suggestions .....	110
<b>4</b>	<b>General discussion and conclusions</b> .....	<b>113</b>
4.1	Choosing the right <i>in vitro</i> investigation approach.....	113
4.2	Formulation enhancement approaches for weakly basic drugs .....	120
4.3	Choosing the right PBPK modeling approach .....	122
4.3.1	Development and evolution of the STELLA® model.....	122



4.3.2	Self-built versus commercial PBPK models (STELLA <sup>®</sup> versus Simcyp <sup>®</sup> ) .....	123
4.3.2.1	<i>Input of release and dissolution profiles</i> .....	124
4.3.2.2	<i>Opportunities for simulating pharmacokinetics of modified release formulations</i> .....	125
4.3.2.3	<i>Input of permeability</i> .....	125
4.3.2.4	<i>Middle-out and Bottom-up modeling approaches</i> .....	126
4.3.2.5	<i>Virtual populations</i> .....	127
4.3.2.6	<i>Summary</i> .....	127
4.4	Outlook .....	128
<b>5</b>	<b>Summary</b> .....	<b>131</b>
<b>6</b>	<b>German Summary (Deutsche Zusammenfassung)</b> .....	<b>137</b>
<b>7</b>	<b>Appendix</b> .....	<b>143</b>
7.1	STELLA <sup>®</sup> sensitivity analysis of cinnarizine plasma profile predictions.....	143
7.2	STELLA <sup>®</sup> sensitivity analysis of atazanavir sulfate plasma profile predictions.....	145
7.3	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine .....	148
7.3.1	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine in the fasted state .....	148
7.3.2	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine in the fed state .....	155
7.3.3	Simcyp <sup>®</sup> sensitivity analysis of cinnarizine plasma profile predictions .....	161
7.3.4	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine using fitted Vd.....	172
7.4	Simcyp <sup>®</sup> plasma profile predictions of atazanavir .....	176
7.4.1	Simcyp <sup>®</sup> plasma profile predictions of atazanavir in the fasted state.....	176
7.4.2	Simcyp <sup>®</sup> plasma profile predictions of atazanavir in the fed state.....	184
7.4.3	Simcyp <sup>®</sup> sensitivity analysis of atazanavir plasma profile predictions.....	188
<b>8</b>	<b>References</b> .....	<b>203</b>
<b>9</b>	<b>Curriculum Vitae</b> .....	<b>216</b>
9.1	Personal Information .....	216
9.2	Professional experience .....	216
9.3	Education .....	217
<b>10</b>	<b>Scientific Publications</b> .....	<b>218</b>
10.1	Papers .....	218
10.2	Posters .....	218
<b>11</b>	<b>Academic Teachers</b> .....	<b>218</b>